TABLE 23Haematological AEs (%)

AEAll gradesGrades 3 and 4
Breccia et al. (2010),9 600 or 800 mg (n = 74)Kantarjian et al. (2009),7 400 mg b.i.d. (n = 49)aKoh et al. (2010),10 600 or 800 mg (n = 71)Rajappa et al. (2010),8 800 mg (n = 90)
Anaemia0, 2b816.930
Leucopenia1631
Neutropenia0, 3b3918.339
Thrombocytopenia14021

AP, accelerated phase; BC, blast crisis; CP, chronic phase.

a

Study included CP (n = 64), AC (n = 3) and BC (n = 4).

b

In 600 mg/day (n = 54) and 800 mg/day (n = 20) subgroups, respectively.

From: 3, Clinical effectiveness

Cover of Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.23.
Loveman E, Cooper K, Bryant J, et al.
Southampton (UK): NIHR Journals Library; 2012 May.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.